studies

lung cancer : non small cell (NSCLC), gene alteration target therapy vs. bevacizumab based treatment, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsNie, 2018 0.79 [0.38; 1.63] 0.79[0.38; 1.63]Nie, 201810%147NAnot evaluable progression or deaths (PFS)detailed resultsNie, 2018 0.23 [0.13; 0.41] 0.23[0.13; 0.41]Nie, 201810%147NAnot evaluable objective responses (ORR)detailed resultsNie, 2018 17.33 [6.66; 45.11] 17.33[6.66; 45.11]Nie, 201810%147NAnot evaluable TRAE leading to death (grade 5)detailed resultsNie, 2018 0.99 [0.02; 50.39] 0.99[0.02; 50.39]Nie, 201810%147NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-30 21:52 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 1413,435,434,1514,1515,474,1513,1390,714,423,424,425,562,426,1472,1400,1396,1468,431,1392,1391,1415,1416,1417,1493,1397,1383,1399,1426,1398,1387,1106,1108,1107,1393,1394,1402,1388,1389,1386,1384,1522,1385,1512,1511,1454